Veena Shankaran, MD, of the Seattle Cancer Care Alliance, discusses study findings from a national sample of patients with metastatic colorectal cancer who are on systemic therapy. A year into their treatment, nearly three out of four patients had major financial hardships despite access to health insurance coverage (Abstract 137).
Joseph M. Unger, PhD, of Fred Hutchinson Cancer Research Center, discusses study results showing that more than half of all patients with cancer, regardless of race or ethnicity, agree to take part in clinical trials, a finding that upends conventional beliefs. He talks about removing the barriers to help more patients participate (Abstract 92).
Marie A. Flannery, PhD, and Eva Culakova, PhD, both of the University of Rochester, discuss a geriatric assessment tool that helped reduce symptomatic toxicities, as measured by Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (Abstract 138).
James D. Murphy, MD, of the University of California, San Diego, discusses the possible reasons for a decline in long-term opioid use in patients with cancer, even as short-term use is rising, as well as the racial and socioeconomic disparities of opioid use in this population (Abstract 187).
Melissa K. Accordino, MD, of Columbia University Medical Center, discusses findings showing nearly half of the patients with breast cancer treated at an academic center in New York City experienced a change or delay in their workup or treatment during the COVID-19 pandemic. Race and socioeconomic factors played a significant role (Abstract 88).
Cardinale B. Smith, MD, PhD, of the Icahn School of Medicine at Mount Sinai, discusses findings showing Black, Hispanic, and Asian patients with cancer used telehealth less often during the COVID-19 pandemic than White patients with cancer, a negative trend that will become more problematic as this method of care continues to increase through subsequent waves of coronavirus infection and plays a larger role in standard treatment (Abstract 87).
